Search

Displaying results 4971 - 4980 of 10000 in total
  1. Drug

    D-JNKI-1

    go.drugbank.com/drugs/DB05660
    Investigational

    A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the

  2. Drug

    MUC1 Dendritic Cell Vaccine

    go.drugbank.com/drugs/DB05477
    Investigational

    These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer. … Dendritic Cell Therapy involves the harvesting of blood cells (ie monocytes or macrophages) from a patient and processing them in the laboratory to produce a greater than typical Dendritic Cell concentration

  3. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib is intended for the treatment of hematologic malignancies and the solid tumors. … Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels

    Synonyms: UREA, N-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-N'-(2-FLUORO-5-METHYLPHENYL)-, N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea
  4. Drug

    Atipamezole

    go.drugbank.com/drugs/DB11481
    InvestigationalVet approved

    It has also been undergone research as a potential anti-Parkinsonian drug for humans. … Atipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs.

  5. Drug

    Mirococept

    go.drugbank.com/drugs/DB06492
    Experimental

    Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI. … It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the

  6. Drug

    Pafuramidine

    go.drugbank.com/drugs/DB06532
    Investigational

    Pafuramidine, a prodrug of furamidine, currently has orphan status for _Pneumocystis jiroveci_ pneumonia.

  7. Drug

    Hydrocortisone acetate

    go.drugbank.com/drugs/DB14539
    ApprovedInvestigationalVet approved

    Mixtures: Actinac Pwr, Alcortin AProducts: Poli-A, Ala Scalp
  8. Drug

    NCX 1022

    go.drugbank.com/drugs/DB05410
    Experimental

    NCX is an NO-releasing derivative of hydrocortisone.

  9. Drug

    Thymectacin

    go.drugbank.com/drugs/DB05116
    Investigational

    Thymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent. … Thymectacin was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer.

  10. Drug

    Zanidatamab zovodotin

    go.drugbank.com/drugs/DB15472
    Experimental

    According to Zymeworks, "ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as [ZW25] but armed with a cytotoxic payload." … [L8234] It is being investigated for several indications characterized by HER2 expression including breast and gastric cancers that have progressed or are refractory to existing HER2-targeted therapies